Lpath Awarded NIH SBIR Grant for Lpathomab

                  Lpath Awarded NIH SBIR Grant for Lpathomab

Funding to study Lpathomab™ in diabetic neuropathic pain and diabetic

PR Newswire

SAN DIEGO, Sept. 23, 2013

SAN DIEGO, Sept. 23, 2013 /PRNewswire/ --Lpath, Inc. (NASDAQ: LPTN), the
industry leader in lipidomics-based therapeutics, announced receipt of a
Notice of Grant Award from the National Institutes of Health (NIH). This
$145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic
monoclonal antibody, Lpathomab™, in animal models of diabetic neuropathic pain
and diabetic neuropathy.

Lpathomab functions like a 'molecular sponge' that binds to and neutralizes
the bioactive lipid signaling molecule, lysophosphatidic acid (LPA). In this
way, the LPA receptors associated with the transmission of pain through the
nervous system are silenced. Lpathomab was discovered using Lpath's
proprietary ImmuneY2™  drug-discovery  technology.

In collaboration with researchers at the University of California, San Diego,
Lpath has already generated strong, reproducible data in an accepted animal
model in which significant pain relief was observed in diabetic rats after
Lpathomab treatment.

The Small Business Innovative Research (SBIR) program of the NATIONAL
(1R43DK098829-01), which will provide Phase 1 funding to conduct in vivo
studies of diabetic neuropathy in diabetic rats that will be treated with
Lpathomab. Diabetic peripheral neuropathy (DPN) is the most common long-term
complication of diabetes mellitus and affects about 50% of patients with
either type-1 or type-2 diabetes. Patients with DPN often experience
debilitating pain symptoms that affect day-to-day functioning and quality of
life. Many patients with DPN-related pain do not respond adequately to any
treatment option currently available, signifying a strong unmet need to
develop new, more efficacious drugs.

"We are pleased the NIH has recognized the value of Lpath's innovative
approach of neutralizing LPA to treat diabetic neuropathic pain," stated Dr.
Rosalia Matteo, associate director at Lpath and the principal investigator on
the grant. "With NIH support, we plan to continue generating compelling data
and advancing Lpathomab, a compound that could potentially fill the tremendous
void that exists in the neuropathic pain market."

About Lpathomab and Lpath's proprietary ImmuneY2™ technology
Lpathomab was generated using Lpath's proprietary ImmuneY2™  technology. This
drug-discovery engine provides Lpath with a unique platform from which to
generate antibodies against bioactive lipids, opening up an entire new array
of drug-discovery possibilities. About 1,000 bioactive members of the lipidome
are believed to exist, but the number could be considerably larger as the
study of lipidomics continues to expand. Nature Reviews stated that bioactive
lipids promise to occupy center-stage in cell-biology research in the twenty
first century. No other company or research institution has demonstrated an
ability to generate therapeutic-grade monoclonal antibodies against lipids.

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is
the category leader in lipidomics-based therapeutics, an emerging field of
medicine that targets bioactive signaling lipids for treating a wide range of
human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability
to generate therapeutic antibodies that bind to and inhibit bioactive lipids
that contribute to disease. The company has developed three drug candidates,
two of which—iSONEP™ for wet AMD and ASONEP™ for cancer—are currently being
investigated in Phase 2 trials. The third candidate, Lpathomab™, is an
anti-LPA antibody that holds promise in neuropathic pain and neurotrauma. For
more information, visit www.Lpath.com.

About Forward-Looking Statements
The Company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding: the potential benefits and therapeutic
uses for Lpathomab, the Company's ability to successfully complete additional
preclinical studies, development activities and clinical trials for Lpathomab;
and the Company's ability to develop additional drug candidates utilizing its
proprietary ImmuneY2 drug discovery process. Actual results may differ
materially from those set forth in this press release due to the risks and
uncertainties inherent in the Company's business, including, without
limitation: the outcome of the final analyses of preclinical studies involving
Lpathomab may vary from the Company's initial conclusions; the results of any
future preclinical studies or clinical trials for Lpathomab may not be
favorable and the Company may never receive regulatory approval for Lpathomab
or any of other its drug candidates; and the Company may not be able to secure
the funds necessary to support its clinical trial and product development
plans. More detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with
the SEC. Such documents may be read free of charge on the SEC's web site at
www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement and the Company undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof. This
caution is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.

Scott R. Pancoast
President and CEO
Lpath, Inc.

Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507

Robert H. Uhl
Managing Director
(858) 356-5932

SOURCE Lpath, Inc.

Website: http://www.Lpath.com
Press spacebar to pause and continue. Press esc to stop.